{
  "success": true,
  "pagesUsed": [
    1,
    7,
    8,
    9,
    11,
    12,
    14,
    16,
    17,
    18,
    19,
    22,
    23,
    24
  ],
  "modelUsed": "gemini-3-flash-preview",
  "narrative": {
    "narrativeContents": [
      {
        "id": "nc_1",
        "name": "PROTOCOL AMENDMENTS",
        "text": "PROTOCOL AMENDMENTS",
        "order": 0,
        "instanceType": "NarrativeContent",
        "sectionNumber": "N/A",
        "sectionTitle": "PROTOCOL AMENDMENTS",
        "sectionType": {
          "id": "24f20cd5-2bcd-4ff2-9e5e-7342ce5059bc",
          "code": "Other",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Other",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_2",
        "name": "SYNOPSIS",
        "text": "SYNOPSIS",
        "order": 1,
        "instanceType": "NarrativeContent",
        "sectionNumber": "N/A",
        "sectionTitle": "SYNOPSIS",
        "sectionType": {
          "id": "566c4a09-4a44-4181-971d-008616eabbf6",
          "code": "Synopsis",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Synopsis",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_3",
        "name": "ABBREVIATIONS",
        "text": "ABBREVIATIONS",
        "order": 2,
        "instanceType": "NarrativeContent",
        "sectionNumber": "N/A",
        "sectionTitle": "ABBREVIATIONS",
        "sectionType": {
          "id": "d0c219a0-f9e9-4646-a868-e27820655c78",
          "code": "Other",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Other",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_4",
        "name": "INTRODUCTION",
        "text": "INTRODUCTION",
        "order": 3,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1",
        "sectionTitle": "INTRODUCTION",
        "sectionType": {
          "id": "c738daec-c594-42fe-b45a-59613b78d796",
          "code": "Introduction",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Introduction",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_4_1",
          "nci_4_2",
          "nci_4_3",
          "nci_4_4",
          "nci_4_5",
          "nci_4_6",
          "nci_4_7",
          "nci_4_8",
          "nci_4_9"
        ]
      },
      {
        "id": "nc_5",
        "name": "OBJECTIVES AND HYPOTHESIS",
        "text": "OBJECTIVES AND HYPOTHESIS",
        "order": 4,
        "instanceType": "NarrativeContent",
        "sectionNumber": "2",
        "sectionTitle": "OBJECTIVES AND HYPOTHESIS",
        "sectionType": {
          "id": "b798fc5d-db9d-433f-a007-ed161317e055",
          "code": "Objectives",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Objectives",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_5_1",
          "nci_5_2"
        ]
      },
      {
        "id": "nc_6",
        "name": "STUDY DESIGN AND RATIONALE",
        "text": "STUDY DESIGN AND RATIONALE",
        "order": 5,
        "instanceType": "NarrativeContent",
        "sectionNumber": "3",
        "sectionTitle": "STUDY DESIGN AND RATIONALE",
        "sectionType": {
          "id": "81f0d6a8-f540-4efc-ba07-21f7186b0a20",
          "code": "Study Design",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Design",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_6_1",
          "nci_6_2"
        ]
      },
      {
        "id": "nc_7",
        "name": "SUBJECT SELECTION",
        "text": "SUBJECT SELECTION",
        "order": 6,
        "instanceType": "NarrativeContent",
        "sectionNumber": "4",
        "sectionTitle": "SUBJECT SELECTION",
        "sectionType": {
          "id": "cf451338-3d36-4bfa-b2db-ba7b30719b8a",
          "code": "Eligibility Criteria",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Eligibility Criteria",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_7_1",
          "nci_7_2",
          "nci_7_3"
        ]
      },
      {
        "id": "nc_8",
        "name": "TREATMENT ALLOCATION AND BLINDING",
        "text": "TREATMENT ALLOCATION AND BLINDING",
        "order": 7,
        "instanceType": "NarrativeContent",
        "sectionNumber": "5",
        "sectionTitle": "TREATMENT ALLOCATION AND BLINDING",
        "sectionType": {
          "id": "653f56e9-9f4b-4a31-90b7-8773e2a337d1",
          "code": "Treatment",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Treatment",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_9",
        "name": "DOSAGE AND ADMINISTRATION",
        "text": "DOSAGE AND ADMINISTRATION",
        "order": 8,
        "instanceType": "NarrativeContent",
        "sectionNumber": "6",
        "sectionTitle": "DOSAGE AND ADMINISTRATION",
        "sectionType": {
          "id": "c1fb4f1a-7095-4ad7-8e7e-083375f967f8",
          "code": "Treatment",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Treatment",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_9_1",
          "nci_9_2",
          "nci_9_3",
          "nci_9_4"
        ]
      }
    ],
    "narrativeContentItems": [
      {
        "id": "nci_4_1",
        "name": "Mantle Cell Lymphoma",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1",
        "sectionTitle": "Mantle Cell Lymphoma"
      },
      {
        "id": "nci_4_2",
        "name": "First-line Treatment for Mantle Cell Lymphoma",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2",
        "sectionTitle": "First-line Treatment for Mantle Cell Lymphoma"
      },
      {
        "id": "nci_4_3",
        "name": "Investigational Product Name and Description",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.3",
        "sectionTitle": "Investigational Product Name and Description"
      },
      {
        "id": "nci_4_4",
        "name": "Summary of Relevant Non-clinical and Clinical Pharmacology Data",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.4",
        "sectionTitle": "Summary of Relevant Non-clinical and Clinical Pharmacology Data"
      },
      {
        "id": "nci_4_5",
        "name": "Clinical Efficacy of Ibrutinib in Mantle Cell Lymphoma",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.5",
        "sectionTitle": "Clinical Efficacy of Ibrutinib in Mantle Cell Lymphoma"
      },
      {
        "id": "nci_4_6",
        "name": "Lymphocytosis and Leukostasis",
        "text": "",
        "order": 5,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.6",
        "sectionTitle": "Lymphocytosis and Leukostasis"
      },
      {
        "id": "nci_4_7",
        "name": "Clinical Safety of Ibrutinib",
        "text": "",
        "order": 6,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.7",
        "sectionTitle": "Clinical Safety of Ibrutinib"
      },
      {
        "id": "nci_4_8",
        "name": "Study Drugs Used as Background Therapy",
        "text": "",
        "order": 7,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.8",
        "sectionTitle": "Study Drugs Used as Background Therapy"
      },
      {
        "id": "nci_4_9",
        "name": "Rationale for the Study",
        "text": "",
        "order": 8,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.9",
        "sectionTitle": "Rationale for the Study"
      },
      {
        "id": "nci_5_1",
        "name": "Objectives",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.1",
        "sectionTitle": "Objectives"
      },
      {
        "id": "nci_5_2",
        "name": "Hypothesis",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.2",
        "sectionTitle": "Hypothesis"
      },
      {
        "id": "nci_6_1",
        "name": "Overview of Study Design",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1",
        "sectionTitle": "Overview of Study Design"
      },
      {
        "id": "nci_6_2",
        "name": "Study Design Rationale",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.2",
        "sectionTitle": "Study Design Rationale"
      },
      {
        "id": "nci_7_1",
        "name": "Inclusion Criteria",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1",
        "sectionTitle": "Inclusion Criteria"
      },
      {
        "id": "nci_7_2",
        "name": "Exclusion Criteria",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.2",
        "sectionTitle": "Exclusion Criteria"
      },
      {
        "id": "nci_7_3",
        "name": "Prohibitions and Restrictions",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.3",
        "sectionTitle": "Prohibitions and Restrictions"
      },
      {
        "id": "nci_9_1",
        "name": "Study Treatment",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.1",
        "sectionTitle": "Study Treatment"
      },
      {
        "id": "nci_9_2",
        "name": "Bendamustine and Rituximab Administration",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.2",
        "sectionTitle": "Bendamustine and Rituximab Administration"
      },
      {
        "id": "nci_9_3",
        "name": "Ibrutinib or Placebo Administration",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.3",
        "sectionTitle": "Ibrutinib or Placebo Administration"
      },
      {
        "id": "nci_9_4",
        "name": "Dose Modification",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.4",
        "sectionTitle": "Dose Modification"
      }
    ],
    "abbreviations": [
      {
        "id": "abbr_1",
        "abbreviatedText": "ASCO",
        "expandedText": "American Society of Clinical Oncology",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_2",
        "abbreviatedText": "AUC0-last",
        "expandedText": "area under the plasma concentration versus time curve from time zero to the time corresponding to the last quantifiable concentration",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_3",
        "abbreviatedText": "BR",
        "expandedText": "bendamustine and rituximab",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_4",
        "abbreviatedText": "BTK",
        "expandedText": "Bruton’s tyrosine kinase",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_5",
        "abbreviatedText": "Cmax",
        "expandedText": "maximum observed plasma concentration",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_6",
        "abbreviatedText": "CNS",
        "expandedText": "central nervous system",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_7",
        "abbreviatedText": "CR",
        "expandedText": "complete response",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_8",
        "abbreviatedText": "CRF",
        "expandedText": "Case Report Form",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_9",
        "abbreviatedText": "CSR",
        "expandedText": "Clinical Study Report",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_10",
        "abbreviatedText": "CT",
        "expandedText": "Computed Tomography",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_11",
        "abbreviatedText": "DMC",
        "expandedText": "Data Monitoring Committee",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_12",
        "abbreviatedText": "ECG",
        "expandedText": "Electrocardiogram",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_13",
        "abbreviatedText": "EQ-5D-5L",
        "expandedText": "EuroQol-5 Dimensions-5 Levels",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_14",
        "abbreviatedText": "FACT-Lym",
        "expandedText": "Functional Assessment of Cancer Therapy-Lymphoma",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_15",
        "abbreviatedText": "FDA",
        "expandedText": "Food and Drug Administration",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_16",
        "abbreviatedText": "FFPE",
        "expandedText": "formalin-fixed paraffin-embedded tumor",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_17",
        "abbreviatedText": "FISH",
        "expandedText": "fluorescence in situ hybridization",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_18",
        "abbreviatedText": "IB",
        "expandedText": "Investigator’s Brochure",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_19",
        "abbreviatedText": "IEC",
        "expandedText": "Independent Ethics Committee",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_20",
        "abbreviatedText": "INR",
        "expandedText": "International Normalized Ratio",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_21",
        "abbreviatedText": "IRB",
        "expandedText": "Institutional Review Board",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_22",
        "abbreviatedText": "IWRS",
        "expandedText": "Interactive Web Response System",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_23",
        "abbreviatedText": "JRD",
        "expandedText": "Janssen Research & Development, LLC",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_24",
        "abbreviatedText": "MCL",
        "expandedText": "Mantle Cell Lymphoma",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_25",
        "abbreviatedText": "MIPI",
        "expandedText": "mantle cell lymphoma international prognostic index",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_26",
        "abbreviatedText": "MRD",
        "expandedText": "minimal residual disease",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_27",
        "abbreviatedText": "MRI",
        "expandedText": "Magnetic Resonance Imaging",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_28",
        "abbreviatedText": "NCI CTCAE",
        "expandedText": "National Cancer Institute Common Terminology Criteria for Adverse Events",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_29",
        "abbreviatedText": "NHL",
        "expandedText": "Non-Hodgkin Lymphoma",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_30",
        "abbreviatedText": "PCR",
        "expandedText": "polymerase chain reaction",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_31",
        "abbreviatedText": "PET",
        "expandedText": "Positron Emission Tomography",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_32",
        "abbreviatedText": "PFS",
        "expandedText": "progression-free survival",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_33",
        "abbreviatedText": "P-gp",
        "expandedText": "P-glycoprotein",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_34",
        "abbreviatedText": "PR",
        "expandedText": "partial response",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_35",
        "abbreviatedText": "PRO",
        "expandedText": "patient-reported outcomes",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_36",
        "abbreviatedText": "R",
        "expandedText": "rituximab",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_37",
        "abbreviatedText": "R-CHOP",
        "expandedText": "rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_38",
        "abbreviatedText": "SAE",
        "expandedText": "serious adverse event",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_39",
        "abbreviatedText": "SJS",
        "expandedText": "Stevens-Johnson Syndrome",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_40",
        "abbreviatedText": "TLS",
        "expandedText": "tumor lysis syndrome",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_41",
        "abbreviatedText": "TTNT",
        "expandedText": "time-to-next treatment",
        "instanceType": "Abbreviation"
      }
    ],
    "summary": {
      "sectionCount": 9,
      "itemCount": 20,
      "abbreviationCount": 41
    },
    "studyDefinitionDocument": {
      "id": "sdd_1",
      "name": "A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",
      "documentType": "Protocol",
      "language": "en",
      "instanceType": "StudyDefinitionDocument",
      "version": "Amendment INT-7",
      "versionDate": "19 December 2019",
      "contentIds": [
        "nc_1",
        "nc_2",
        "nc_3",
        "nc_4",
        "nc_5",
        "nc_6",
        "nc_7",
        "nc_8",
        "nc_9"
      ]
    }
  },
  "rawResponse": {
    "abbreviations": {
      "abbreviations": [
        {
          "abbreviation": "ASCO",
          "expansion": "American Society of Clinical Oncology"
        },
        {
          "abbreviation": "AUC0-last",
          "expansion": "area under the plasma concentration versus time curve from time zero to the time corresponding to the last quantifiable concentration"
        },
        {
          "abbreviation": "BR",
          "expansion": "bendamustine and rituximab"
        },
        {
          "abbreviation": "BTK",
          "expansion": "Bruton’s tyrosine kinase"
        },
        {
          "abbreviation": "Cmax",
          "expansion": "maximum observed plasma concentration"
        },
        {
          "abbreviation": "CNS",
          "expansion": "central nervous system"
        },
        {
          "abbreviation": "CR",
          "expansion": "complete response"
        },
        {
          "abbreviation": "CRF",
          "expansion": "Case Report Form"
        },
        {
          "abbreviation": "CSR",
          "expansion": "Clinical Study Report"
        },
        {
          "abbreviation": "CT",
          "expansion": "Computed Tomography"
        },
        {
          "abbreviation": "DMC",
          "expansion": "Data Monitoring Committee"
        },
        {
          "abbreviation": "ECG",
          "expansion": "Electrocardiogram"
        },
        {
          "abbreviation": "EQ-5D-5L",
          "expansion": "EuroQol-5 Dimensions-5 Levels"
        },
        {
          "abbreviation": "FACT-Lym",
          "expansion": "Functional Assessment of Cancer Therapy-Lymphoma"
        },
        {
          "abbreviation": "FDA",
          "expansion": "Food and Drug Administration"
        },
        {
          "abbreviation": "FFPE",
          "expansion": "formalin-fixed paraffin-embedded tumor"
        },
        {
          "abbreviation": "FISH",
          "expansion": "fluorescence in situ hybridization"
        },
        {
          "abbreviation": "IB",
          "expansion": "Investigator’s Brochure"
        },
        {
          "abbreviation": "IEC",
          "expansion": "Independent Ethics Committee"
        },
        {
          "abbreviation": "INR",
          "expansion": "International Normalized Ratio"
        },
        {
          "abbreviation": "IRB",
          "expansion": "Institutional Review Board"
        },
        {
          "abbreviation": "IWRS",
          "expansion": "Interactive Web Response System"
        },
        {
          "abbreviation": "JRD",
          "expansion": "Janssen Research & Development, LLC"
        },
        {
          "abbreviation": "MCL",
          "expansion": "Mantle Cell Lymphoma"
        },
        {
          "abbreviation": "MIPI",
          "expansion": "mantle cell lymphoma international prognostic index"
        },
        {
          "abbreviation": "MRD",
          "expansion": "minimal residual disease"
        },
        {
          "abbreviation": "MRI",
          "expansion": "Magnetic Resonance Imaging"
        },
        {
          "abbreviation": "NCI CTCAE",
          "expansion": "National Cancer Institute Common Terminology Criteria for Adverse Events"
        },
        {
          "abbreviation": "NHL",
          "expansion": "Non-Hodgkin Lymphoma"
        },
        {
          "abbreviation": "PCR",
          "expansion": "polymerase chain reaction"
        },
        {
          "abbreviation": "PET",
          "expansion": "Positron Emission Tomography"
        },
        {
          "abbreviation": "PFS",
          "expansion": "progression-free survival"
        },
        {
          "abbreviation": "P-gp",
          "expansion": "P-glycoprotein"
        },
        {
          "abbreviation": "PR",
          "expansion": "partial response"
        },
        {
          "abbreviation": "PRO",
          "expansion": "patient-reported outcomes"
        },
        {
          "abbreviation": "R",
          "expansion": "rituximab"
        },
        {
          "abbreviation": "R-CHOP",
          "expansion": "rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone"
        },
        {
          "abbreviation": "SAE",
          "expansion": "serious adverse event"
        },
        {
          "abbreviation": "SJS",
          "expansion": "Stevens-Johnson Syndrome"
        },
        {
          "abbreviation": "TLS",
          "expansion": "tumor lysis syndrome"
        },
        {
          "abbreviation": "TTNT",
          "expansion": "time-to-next treatment"
        }
      ]
    },
    "structure": {
      "document": {
        "title": "A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma",
        "version": "Amendment INT-7",
        "versionDate": "19 December 2019"
      },
      "sections": [
        {
          "number": "N/A",
          "title": "PROTOCOL AMENDMENTS",
          "type": "Other"
        },
        {
          "number": "N/A",
          "title": "SYNOPSIS",
          "type": "Synopsis"
        },
        {
          "number": "N/A",
          "title": "ABBREVIATIONS",
          "type": "Other"
        },
        {
          "number": "1",
          "title": "INTRODUCTION",
          "type": "Introduction",
          "subsections": [
            {
              "number": "1.1",
              "title": "Mantle Cell Lymphoma"
            },
            {
              "number": "1.2",
              "title": "First-line Treatment for Mantle Cell Lymphoma"
            },
            {
              "number": "1.3",
              "title": "Investigational Product Name and Description"
            },
            {
              "number": "1.4",
              "title": "Summary of Relevant Non-clinical and Clinical Pharmacology Data"
            },
            {
              "number": "1.5",
              "title": "Clinical Efficacy of Ibrutinib in Mantle Cell Lymphoma"
            },
            {
              "number": "1.6",
              "title": "Lymphocytosis and Leukostasis"
            },
            {
              "number": "1.7",
              "title": "Clinical Safety of Ibrutinib"
            },
            {
              "number": "1.8",
              "title": "Study Drugs Used as Background Therapy"
            },
            {
              "number": "1.9",
              "title": "Rationale for the Study"
            }
          ]
        },
        {
          "number": "2",
          "title": "OBJECTIVES AND HYPOTHESIS",
          "type": "Objectives",
          "subsections": [
            {
              "number": "2.1",
              "title": "Objectives"
            },
            {
              "number": "2.2",
              "title": "Hypothesis"
            }
          ]
        },
        {
          "number": "3",
          "title": "STUDY DESIGN AND RATIONALE",
          "type": "Study Design",
          "subsections": [
            {
              "number": "3.1",
              "title": "Overview of Study Design"
            },
            {
              "number": "3.2",
              "title": "Study Design Rationale"
            }
          ]
        },
        {
          "number": "4",
          "title": "SUBJECT SELECTION",
          "type": "Eligibility Criteria",
          "subsections": [
            {
              "number": "4.1",
              "title": "Inclusion Criteria"
            },
            {
              "number": "4.2",
              "title": "Exclusion Criteria"
            },
            {
              "number": "4.3",
              "title": "Prohibitions and Restrictions"
            }
          ]
        },
        {
          "number": "5",
          "title": "TREATMENT ALLOCATION AND BLINDING",
          "type": "Treatment"
        },
        {
          "number": "6",
          "title": "DOSAGE AND ADMINISTRATION",
          "type": "Treatment",
          "subsections": [
            {
              "number": "6.1",
              "title": "Study Treatment"
            },
            {
              "number": "6.2",
              "title": "Bendamustine and Rituximab Administration"
            },
            {
              "number": "6.3",
              "title": "Ibrutinib or Placebo Administration"
            },
            {
              "number": "6.4",
              "title": "Dose Modification"
            }
          ]
        }
      ]
    }
  }
}